Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis

John L. Johnson, R. Moses Kamya, Alphonse Okwera, Anita M. Loughlin, Sam Nyole, David L. Hom, Robert S. Wallis, Christina S. Hirsch, Kathy Wolski, John Foulds, Roy D. Mugerwa, Jerrold J. Ellner

Research output: Contribution to journalArticle

Abstract

Adjunctive immunotherapy with heat-killed Mycobacterium vaccae was studied in a randomized, placebo-controlled trial of 120 non-human immunodeficiency virus-infected adults with newly diagnosed pulmonary tuberculosis. Patients were randomized to a single dose of M. vaccae or placebo 1 week after beginning chemotherapy and were followed up for 1 year. M. vaccae was safe and well tolerated. The rate of sputum culture conversion after 1 month of tuberculosis treatment was 35% in the M. vaccae group and only 14% in the placebo group (P = .01) but was comparable at 2 months and thereafter. Patients receiving M. vaccae had greater improvement on chest radiography at 6 months (91% vs. 77% for placebo recipients; P = .04) and 12 months (94% vs. 80%; P = .04) after initiation of tuberculosis treatment. These data provide evidence of an early increase in sputum culture conversion and greater radiographic improvement among patients who received M. vaccae. Further studies are warranted.

Original languageEnglish (US)
Pages (from-to)1304-1312
Number of pages9
JournalJournal of Infectious Diseases
Volume181
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Mycobacterium
Pulmonary Tuberculosis
Immunotherapy
Randomized Controlled Trials
Placebos
Viruses
Sputum
Tuberculosis
Radiography
Thorax
Hot Temperature
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. / Johnson, John L.; Kamya, R. Moses; Okwera, Alphonse; Loughlin, Anita M.; Nyole, Sam; Hom, David L.; Wallis, Robert S.; Hirsch, Christina S.; Wolski, Kathy; Foulds, John; Mugerwa, Roy D.; Ellner, Jerrold J.

In: Journal of Infectious Diseases, Vol. 181, No. 4, 2000, p. 1304-1312.

Research output: Contribution to journalArticle

Johnson, JL, Kamya, RM, Okwera, A, Loughlin, AM, Nyole, S, Hom, DL, Wallis, RS, Hirsch, CS, Wolski, K, Foulds, J, Mugerwa, RD & Ellner, JJ 2000, 'Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis', Journal of Infectious Diseases, vol. 181, no. 4, pp. 1304-1312. https://doi.org/10.1086/315393
Johnson, John L. ; Kamya, R. Moses ; Okwera, Alphonse ; Loughlin, Anita M. ; Nyole, Sam ; Hom, David L. ; Wallis, Robert S. ; Hirsch, Christina S. ; Wolski, Kathy ; Foulds, John ; Mugerwa, Roy D. ; Ellner, Jerrold J. / Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. In: Journal of Infectious Diseases. 2000 ; Vol. 181, No. 4. pp. 1304-1312.
@article{ece046c899734b34800a4a418b4eed8e,
title = "Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis",
abstract = "Adjunctive immunotherapy with heat-killed Mycobacterium vaccae was studied in a randomized, placebo-controlled trial of 120 non-human immunodeficiency virus-infected adults with newly diagnosed pulmonary tuberculosis. Patients were randomized to a single dose of M. vaccae or placebo 1 week after beginning chemotherapy and were followed up for 1 year. M. vaccae was safe and well tolerated. The rate of sputum culture conversion after 1 month of tuberculosis treatment was 35{\%} in the M. vaccae group and only 14{\%} in the placebo group (P = .01) but was comparable at 2 months and thereafter. Patients receiving M. vaccae had greater improvement on chest radiography at 6 months (91{\%} vs. 77{\%} for placebo recipients; P = .04) and 12 months (94{\%} vs. 80{\%}; P = .04) after initiation of tuberculosis treatment. These data provide evidence of an early increase in sputum culture conversion and greater radiographic improvement among patients who received M. vaccae. Further studies are warranted.",
author = "Johnson, {John L.} and Kamya, {R. Moses} and Alphonse Okwera and Loughlin, {Anita M.} and Sam Nyole and Hom, {David L.} and Wallis, {Robert S.} and Hirsch, {Christina S.} and Kathy Wolski and John Foulds and Mugerwa, {Roy D.} and Ellner, {Jerrold J.}",
year = "2000",
doi = "10.1086/315393",
language = "English (US)",
volume = "181",
pages = "1304--1312",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis

AU - Johnson, John L.

AU - Kamya, R. Moses

AU - Okwera, Alphonse

AU - Loughlin, Anita M.

AU - Nyole, Sam

AU - Hom, David L.

AU - Wallis, Robert S.

AU - Hirsch, Christina S.

AU - Wolski, Kathy

AU - Foulds, John

AU - Mugerwa, Roy D.

AU - Ellner, Jerrold J.

PY - 2000

Y1 - 2000

N2 - Adjunctive immunotherapy with heat-killed Mycobacterium vaccae was studied in a randomized, placebo-controlled trial of 120 non-human immunodeficiency virus-infected adults with newly diagnosed pulmonary tuberculosis. Patients were randomized to a single dose of M. vaccae or placebo 1 week after beginning chemotherapy and were followed up for 1 year. M. vaccae was safe and well tolerated. The rate of sputum culture conversion after 1 month of tuberculosis treatment was 35% in the M. vaccae group and only 14% in the placebo group (P = .01) but was comparable at 2 months and thereafter. Patients receiving M. vaccae had greater improvement on chest radiography at 6 months (91% vs. 77% for placebo recipients; P = .04) and 12 months (94% vs. 80%; P = .04) after initiation of tuberculosis treatment. These data provide evidence of an early increase in sputum culture conversion and greater radiographic improvement among patients who received M. vaccae. Further studies are warranted.

AB - Adjunctive immunotherapy with heat-killed Mycobacterium vaccae was studied in a randomized, placebo-controlled trial of 120 non-human immunodeficiency virus-infected adults with newly diagnosed pulmonary tuberculosis. Patients were randomized to a single dose of M. vaccae or placebo 1 week after beginning chemotherapy and were followed up for 1 year. M. vaccae was safe and well tolerated. The rate of sputum culture conversion after 1 month of tuberculosis treatment was 35% in the M. vaccae group and only 14% in the placebo group (P = .01) but was comparable at 2 months and thereafter. Patients receiving M. vaccae had greater improvement on chest radiography at 6 months (91% vs. 77% for placebo recipients; P = .04) and 12 months (94% vs. 80%; P = .04) after initiation of tuberculosis treatment. These data provide evidence of an early increase in sputum culture conversion and greater radiographic improvement among patients who received M. vaccae. Further studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0034066912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034066912&partnerID=8YFLogxK

U2 - 10.1086/315393

DO - 10.1086/315393

M3 - Article

C2 - 10753731

AN - SCOPUS:0034066912

VL - 181

SP - 1304

EP - 1312

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -